Extended rituximab schedules may result in increased efficacy in pulmonary malt lymphoma.
Seker
Mesut
M
Bilici
Ahmet
A
Ustaalioglu
Basak Oven
BO
Salman
Tarik
T
Sonmez
Berkant
B
Canpolat
Nesrin A
NA
Salepci
Taflan
T
Gumus
Mahmut
M
Yaylaci
Mustafa
M
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D018442:Lymphoma, B-Cell, Marginal Zone / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008875:Middle Aged; D000069283:Rituximab; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab